PEGylated form of thymalin with extended half-life designed for less frequent dosing. Studied for prolonged immune restoration and longevity applications. Pegylation technology applied to thymic peptide class.
Extended vs standard thymalin; days-week depending on PEG molecular weight used
SKUs
1
Evidence
Emerging
PEG-Thymalin is a PEGylated form of Thymalin — a thymus-derived peptide preparation developed through Russian bioregulator research. PEGylation (attaching polyethylene glycol chains) is a technique used to extend the half-life of peptides in circulation and reduce immune recognition. Thymalin itself has been studied for immune system support and aging; the PEGylated version aims to improve its pharmacokinetic profile.
Immune Function Research
Thymalin, the base compound, has been studied in Russian clinical research for restoring immune function in elderly patients, cancer patients receiving chemotherapy, and people with various immune-compromising conditions. Research reported normalization of T-cell populations and improvements in immune function markers.
Aging and Longevity Research
Thymalin has been included in Russian longevity research programs. Studies in elderly individuals reported improvements in longevity markers, cardiovascular indicators, and immune competence. The thymus gland — which produces Thymalin — shrinks with age, and researchers have explored whether supplementing thymic peptides can partially compensate.
PEGylation Pharmacology Research
PEGylation of short peptides is a pharmaceutical strategy to extend their useful life in the body. The PEG modification of Thymalin is designed to increase circulation time, potentially allowing less frequent dosing. This is more a pharmaceutical engineering area than a new mechanism of action.
Thymalin base compound has Russian clinical data showing immune normalization in elderly and immunocompromised patients.
Some longevity-related improvements in immune and cardiovascular markers in elderly subjects.
PEGylation as a strategy is well-established for extending peptide half-life.
PEG-specific human trial data for PEG-Thymalin specifically are very limited.
The research base for Thymalin comes predominantly from Russian studies, which may have methodological limitations and have not been independently replicated in large Western trials. PEG-Thymalin as a specific form has very limited published research data. It is not FDA-approved. The immune research context — primarily for elderly or medically compromised patients — may not generalize to healthy individuals.
The thymus gland sits behind the breastbone and plays a central role in training T-cells — the immune cells that distinguish the body's own tissue from threats. Thymalin is a preparation of peptides extracted from thymus tissue that is thought to carry signaling molecules similar to those the thymus uses to regulate immune function. As people age, the thymus gradually shrinks and becomes less active, which is associated with declining immune competence. The idea behind thymic peptide supplementation is to provide external signals that partially substitute for what the aging thymus is no longer producing. PEGylation extends how long those signals remain active in circulation.
Thymalin has been used in Russian clinical practice for decades without notable safety concerns in published literature. PEG-Thymalin specifically has a very limited published safety profile. PEG itself is generally considered safe and is used in many approved medications and food products. It is not FDA-approved. As with all non-approved research peptides, research-grade purity and sterility are critical considerations.
Emerging
This compound is in early-stage research. Evidence is limited to small studies or in vitro data.
Published Research Ranges
Experimental; optimal dosing under investigation; less frequent administration by design (weekly/biweekly vs daily)
Research Context Only: These are ranges reported in published scientific studies for educational reference. They are not dosing recommendations. This is not medical advice. Always consult a qualified healthcare professional.
Sources listed here are from the platform research library. All links open the original publication. No citations are generated by AI.
PEGylated Thymalin: Extended Half-Life and Preserved Immunological Activity
Bulletin of Experimental Biology and Medicine • 2009
• DOI: 10.1007/s10517-009-0535-5
Biogenic Selenium Nanoparticles in Biomedical Sciences: Properties, Current Trends, Novel Opportunities and Emerging Challenges in Theranostic Nanomedicine
Research Education Only: This profile is for educational purposes only. All information is sourced from published scientific literature. This is not medical advice. Not for human consumption. Consult qualified medical professionals for any health decisions.
We use cookies to enhance your research experience and analyze platform usage. By continuing, you agree to our Cookie Policy.